Yes, then A2-73 plus Aricept would be considered for approval due to them being dosed together. That is what we want. If the Anavex Plus patent goes thru it will be good until 2033.
If the patent doesn't go thru, then A2-73 gets 4 or 5 years (I've seen both numbers mentioned) of market exclusivity.
Not sure, but, it would seem likely that A2-73's market exclusivity could be extended with each approval of an Orphan Drug Designation.
News 
Market Data 
Discover 
AI
